Schizophrenia, Schizoaffective Disorder Clinical Trial
Official title:
A Multi-center, Open-label, Randomized, Parallel-group Trial to Characterize the Pharmacokinetics of Three SC Olanzapine Extended-Release Formulations With Different Release Rates Following Single Administration in Participants With Schizophrenia or Schizoaffective Disorder
The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine. Another secondary objective is to characterize the pharmacokinetics of ZYPREXA. The planned duration of the study for each participant is 19 weeks.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04512066 -
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
|
Phase 2 | |
| Completed |
NCT02192593 -
Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations
|
N/A | |
| Completed |
NCT00224315 -
Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial
|
Phase 4 | |
| Recruiting |
NCT02808533 -
Topiramate and Schizophrenia: Effects on Weight and Psychopathology
|
N/A | |
| Terminated |
NCT03669640 -
A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
|
Phase 2 |